FDA Clarifies Drug Interaction Study Requirements, Labeling Expectations

FDA officials say drug manufacturers may be able to establish dosing recommendations and characterize drug-drug interaction risks without conducting additional clinical studies, including through pharmacokinetic modeling and real-world data, provided the evidence is scientifically justified.

During a series of FDA presentations released 11/4 on [Drug Interaction Information in Prescription Labeling], [QTc Interval Prolongation Labeling] and a [Follow-Up Question-and-Answer Panel], Kellie Schoolar Reynolds, acting deputy director of CDER's Office of Clinical Pharmacology, said additional efficacy or safety studies are rarely necessary when sponsors recommend dosage changes based on drug interaction findings.

FDA can often predict the effects of alternative dosing regimens using existing interaction studies, clinical pharmacology information and knowledge of the interaction mechanism, she said. In some cases, additional pharmacokinetic studies are unnecessary.

Reynolds also confirmed that real-world assessments using sparse pharmacokinetic sampling may be acceptable when dedicated drug interaction studies are impractical because of treatment toxicity, including for oncology drugs. Sponsors should establish their analytical plans in advance and consult FDA review divisions before proceeding.

The agency's 8/2024 ICH M12 guidance provides a framework for determining when in vivo drug interaction studies are necessary. Reynolds said sponsors may conclude such studies are unnecessary when available evidence adequately excludes clinically significant interactions.

FDA Clarifies Labeling Expectations

CDER Labeling Policy Team director Eric Brodsky said drug interaction labeling should provide specific, actionable instructions rather than vague recommendations such as "use with caution" or "adjust dosage." When existing labeling is inaccurate or potentially misleading, sponsors should correct it through a supplement. However, when instructions are merely ambiguous, FDA generally recommends addressing the issue in the next supplement rather than treating it as urgent.

Brodsky also recommended identifying interacting drug classes rather than listing individual medications when all members of a class share a clinically significant interaction. Individual drugs should be identified when their clinical effects or management recommendations differ.

FDA Division of Cardiology and Nephrology associate director Christine Garnett reviewed the agency's 12/2025 guidance on communicating QTc interval prolongation risks in prescription drug labeling. She said Boxed Warnings may be warranted when evidence links a drug to torsades de pointes, serious arrhythmias or other life-threatening cardiac events. Extensive QTc prolongation, such as a mean increase exceeding 20 milliseconds in a population at high risk of arrhythmias, may also support a Boxed Warning.

Labeling should provide specific ECG monitoring instructions, dose modification thresholds and recommendations for interrupting or discontinuing treatment when clinically significant QTc prolongation occurs.

Garnett cautioned that emerging postmarketing reports of QTc prolongation require careful assessment before being elevated to warnings and precautions or prompting dosage changes. FDA considers alternative explanations, including underlying diseases and concomitant medications, and may request additional evidence to establish a causal relationship.

Additional Regulatory Clarifications

The officials addressed several other questions concerning labeling and drug development:

• Contraindications versus avoid-use recommendations: Reynolds said contraindications generally mean two drugs should not be administered together under any circumstances because of serious toxicity or loss of essential efficacy. Avoid-use recommendations may permit concomitant treatment when alternatives are unavailable and risks can be managed through close medical supervision.
• Postmarketing studies: Results from drug interaction studies conducted under postmarketing requirements or commitments may lead to updates in Section 12, Clinical Pharmacology, and Section 7, Drug Interactions, when clinically actionable findings emerge.
• Older drugs: Garnett acknowledged that some drugs approved decades ago were not evaluated using modern QT assessment methods. Additional studies may be appropriate, particularly when older products are being repurposed for new indications.
• Insufficient QTc data: Garnett clarified that labeling should acknowledge insufficient information to characterize QTc effects when an adequate assessment was not completed during development, even if the drug is not already known to prolong the QT interval. Additional postmarketing assessment may be necessary.
• QT assessments for newer modalities: Garnett said drugs with systemic bioavailability generally require QT assessment, although certain therapeutic proteins and other modalities may qualify for exceptions when there is no mechanistic basis for concern. Nonclinical findings suggesting cardiac effects may nevertheless warrant clinical evaluation.